Genentech adds to breast cancer pipeline with Seragon buyout

02-07-2014

Genentech adds to breast cancer pipeline with Seragon buyout

sparkstudio / Shutterstock.com

Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.725 billion.


Genentech, Seragon, breast cancer, ARN-810, mergers and acquisitions

LSIPR